<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="593">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 13, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02247401</url>
  </required_header>
  <id_info>
    <org_study_id>M14-250</org_study_id>
    <nct_id>NCT02247401</nct_id>
  </id_info>
  <brief_title>Coadministration of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) With Ribavirin (RBV) in Adults With Genotype 4 (GT4) Hepatitis C Virus (HCV) in Egypt</brief_title>
  <official_title>An Open-Label Study to Evaluate the Safety and Efficacy of the Coadministration of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) With Ribavirin (RBV) in Adults With Chronic Hepatitis C Virus Genotype 4 Infection in Egypt</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <authority>Egypt: Institutional Review Board</authority>
    <authority>Egypt: Ministry of Health and Population</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the efficacy and safety of ABT-450/r/ABT-267 with RBV in treatment
      naive and treatment experienced HCV GT4 subjects without or with compensated cirrhosis.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>November 2014</start_date>
  <completion_date type="Anticipated">August 2016</completion_date>
  <primary_completion_date type="Anticipated">June 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Percentage of subjects with sustained virologic response 12 weeks post-treatment (SVR12) in each arm</measure>
    <time_frame>12 weeks after last dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>SVR12 is defined as Hepatitis C virus ribonucleic acid (HCV RNA) less than the lower limit of quantification (&lt; LLOQ) 12 weeks after the last dose of study drug.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Adverse Events</measure>
    <time_frame>Screening until 30 days after last dose</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with on-treatment virologic failure in each treatment arm</measure>
    <time_frame>Up to 12 or 24 weeks after first dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>On-treatment virologic failure is defined as quantifiable hepatitis C virus ribonucleic acid through out the entire treatment period with at least 6 weeks of treatment, confirmed greater than the lower limit of quantification hepatitis C virus ribonucleic acid after previously having unquantifiable hepatitis C virus ribonucleic acid, or a confirmed increase from nadir of at least one log10 in hepatitis C virus ribonucleic acid during treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with post-treatment relapse within 12 weeks following end of treatment in each arm</measure>
    <time_frame>Up to 12 weeks after first dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Virologic relapse after treatment is defined as confirmed &gt; the lower limit of quantification (LLOQ) plasma hepatitis C virus ribonucleic acid (HCV RNA) between the end of treatment and 12 weeks after the last dose of study drug among subjects who completed treatment with HCV RNA &lt; LLOQ at the end of treatment.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>HCV</condition>
  <condition>Hepatitis C Infection</condition>
  <condition>Genotype 4</condition>
  <arm_group>
    <arm_group_label>Substudy 1 - 2 DAA + RBV without cirrhosis for 12 weeks</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ABT-450/r/ABT-267 plus RBV for 12 weeks in treatment naive and treatment experienced (with pegylated interferon and ribavirin) subjects without cirrhosis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Substudy 2 - 2 DAA + RBV with cirrhosis for 12 weeks</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ABT-450/r/ABT-267 plus RBV for 12 weeks in treatment naive and treatment experienced (with pegylated interferon and ribavirin) subjects with compensated cirrhosis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Substudy 2 - 2 DAA + RBV with cirrhosis for 24 weeks</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ABT-450/r/ABT-267 plus RBV for 24 weeks in treatment naive and treatment experienced (with pegylated interferon and ribavirin) subjects with compensated cirrhosis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>2 DAA</intervention_name>
    <description>ABT-450/r/ABT-267 tablets</description>
    <arm_group_label>Substudy 1 - 2 DAA + RBV without cirrhosis for 12 weeks</arm_group_label>
    <arm_group_label>Substudy 2 - 2 DAA + RBV with cirrhosis for 12 weeks</arm_group_label>
    <arm_group_label>Substudy 2 - 2 DAA + RBV with cirrhosis for 24 weeks</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RBV</intervention_name>
    <description>Ribavirin tablets</description>
    <arm_group_label>Substudy 1 - 2 DAA + RBV without cirrhosis for 12 weeks</arm_group_label>
    <arm_group_label>Substudy 2 - 2 DAA + RBV with cirrhosis for 12 weeks</arm_group_label>
    <arm_group_label>Substudy 2 - 2 DAA + RBV with cirrhosis for 24 weeks</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: -Chronic hepatitis C, genotype 4-infection (HCV RNA level greater than
        1,000 IU/mL at Screening)

          -  Subjects must meet one of the following:

               -  Treatment-naive: Subject has never received antiviral treatment for hepatitis C
                  infection OR

               -  Treatment Experienced (Prior null responders, Partial responders or Relapsers to
                  pegIFN/RBV);

          -  Females must be post-menopausal, of non-child bearing potential or practicing
             specific forms of birth control

          -  In substudy 1, demonstrated absence of liver cirrhosis as confirmed by liver biopsy
             or Fibroscan

          -  In substudy 2, evidence of liver cirrhosis as confirmed by liver biopsy or Fibroscan
             with Child-Pugh score less than or equal to 6 at Screening and confirmed absence of
             hepatocellular carcinoma

        Exclusion Criteria: - Females who are pregnant or breastfeeding

          -  Positive screen for hepatitis B Surface antigen or anti-Human Immunodeficiency virus
             antibody

          -  HCV genotype performed during screening indicating unable to genotype or co-infection
             with any other HCV genotype

          -  abnormal laboratory tests

          -  self-reports current drinking more than 2 drinks per day

          -  current enrollment in another investigational study

          -  previous treatment with a direct acting antiviral agent (DAA) containing regimen

          -  In substudy 1, evidence of liver cirrhosis

          -  In substudy 2, evidence of current or past Child-Pugh B or C classification and
             confirmed presence of hepatocellular carcinoma
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roula Qaqish, PharmD</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 127895</name>
      <address>
        <city>Cairo</city>
        <zip>11559</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 127940</name>
      <address>
        <city>Cairo</city>
        <zip>11441</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 128857</name>
      <address>
        <city>Cairo</city>
        <zip>11652</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 127941</name>
      <address>
        <city>Dakahliah</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 127899</name>
      <address>
        <city>Menoufiya</city>
        <zip>35111</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <lastchanged_date>October 16, 2015</lastchanged_date>
  <firstreceived_date>September 19, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>non-responder</keyword>
  <keyword>Egypt</keyword>
  <keyword>HCV</keyword>
  <keyword>null responder</keyword>
  <keyword>Genotype 4</keyword>
  <keyword>compensated cirrhosis</keyword>
  <keyword>naive</keyword>
  <keyword>treatment experienced</keyword>
  <keyword>hepatitis c</keyword>
  <keyword>relapser</keyword>
  <keyword>hepatitis infection</keyword>
  <keyword>partial responder</keyword>
  <keyword>Cirrhosis</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Infection</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ribavirin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
